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Abstract
Norwalk virus and human papilloma virus, two viruses that infect humans at mucosal surfaces, have been found capable of
rapidly penetrating human mucus secretions. Viral vectors for gene therapy of Cystic Fibrosis (CF) must similarly penetrate
purulent lung airway mucus (sputum) to deliver DNA to airway epithelial cells. However, surprisingly little is known about
the rates at which gene delivery vehicles penetrate sputum, including viral vectors used in clinical trials for CF gene therapy.
We find that sputum spontaneously expectorated by CF patients efficiently traps two viral vectors commonly used in CF
gene therapy trials, adenovirus (d,80 nm) and adeno-associated virus (AAV serotype 5; d,20 nm), leading to average
effective diffusivities that are ,3,000-fold and 12,000-fold slower than their theoretical speeds in water, respectively. Both
viral vectors are slowed by adhesion, as engineered muco-inert nanoparticles with diameters as large as 200 nm penetrate
the same sputum samples at rates only ,40-fold reduced compared to in pure water. A limited fraction of AAV exhibit
sufficiently fast mobility to penetrate physiologically thick sputum layers, likely because of the lower viscous drag and
smaller surface area for adhesion to sputum constituents. Nevertheless, poor penetration of CF sputum is likely a major
contributor to the ineffectiveness of viral vector based gene therapy in the lungs of CF patients observed to date.
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Introduction
Nearly 20 years of clinical and laboratory research has thus far
failed to realize successful gene therapy for cystic fibrosis (CF)
[1,2]. Viral gene vectors have dominated gene therapy efforts for
CF, with adenovirus (AdV) and adeno-associated virus (AAV)
representing two of the most widely tested systems to date [1,2].
Although significant gene transfer has been observed for AdV and
AAV vectors in cell lines and in a variety of animal models [3–5],
neither vector has provided sufficient therapeutic end points in CF
patients. Poor gene transfer has been attributed primarily to
limited cellular uptake across the apical membrane of the lung
airways, unproductive intracellular trafficking, vector toxicity, and
immunological barriers [6].
We reasoned the CF sputum is a largely overlooked bottleneck
that may limit gene therapy directed to the airways of CF patients.
CF sputum possesses a bulk viscosity as high as 10
4–10
5 -fold
greater than that of water at low shear [7,8], and, thus, may
physically exclude gene vectors from reaching epithelial cells.
Although some viruses that infect mucosal surfaces (e.g. human
papilloma virus and Norwalk virus) diffuse through human
ovulatory cervical mucus as fast as through water [9], we recently
found that other viruses (e.g. HIV and Herpes Simplex Virus) can
be extensively trapped in non-ovulatory human cervicovaginal
mucus collected from donors with healthy vaginal flora [10,11].
Little is known about the ability of viral gene carriers commonly
used in humans to penetrate CF sputum.
To investigate whether CF airway sputum serves as a transport
barrier to viral vectors most commonly used in clinical trials, we
performed high resolution multiple particle tracking (MPT)
[12,13] on both AdV and AAV serotype 5 (AAV5) in fresh,
undiluted purulent sputum expectorated by CF patients. Although
the average mesh spacing in purulent CF sputum (d ,
140650 nm; range 60–300 nm) is substantially smaller than that
in human cervicovaginal mucus (d ,340670 nm; range 50–
1800 nm), the openings are sufficiently large that both AdV (d
,80 nm) and AAV5 (d ,20 nm) should readily penetrate CF
sputum if they are not slowed by adhesive interactions with
sputum constituents [11,14].
Results and Discussion
Despite their native tropism for infecting airway cells, the
diffusion of both AdV and AAV5 was strongly hindered in five of
five independent human sputum samples. The highly constrained
virus trajectories (Figure 1A & 1B) were similar to uncoated
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sputum (Figure 1C). We also tested 200 nm PS beads that were
densely coated with low MW polyethylene glycol (PS-PEG), which
we previously found to exhibit minimal adhesion to human mucus
and CF sputum [11,12,14]. The PS-PEG particles exhibited traces
spanning distances far larger than their diameters over the same
duration in the same sputum samples (Figure 1D). We quantified
the translational motions of particles and viruses by their time-
scale dependent ensemble mean squared displacements
(,MSD.). The ensemble-averaged ,MSD. for AdV, AAV5
and muco-adhesive PS beads were all smaller than 10
22 mm
2
across the time scales measured, whereas the ,MSD. value for
PS-PEG was at least 20-fold greater at a time scale of 1 s (Figure 2).
AdV and AAV5 were slowed by over 3,000 and 12,000-fold in
sputum compared to their theoretical speeds in water, respectively.
In contrast, 200 nm PS-PEG particles were only slowed 40-fold in
sputum as compared to in water. By fitting MSD vs. time scale (t)
to the equation MSD =4D0t
a, where D0 is the time scale-
independent diffusion coefficient, an average value for a can be
obtained that provides insight into the extent of impediment to
particle motion (a=1 for purely Brownian, unobstructed diffusion;
the lower the value of a, the more constrained the particle motion).
The average a-value of AdV and AAV5 (,0.37 for each) is
comparable to that for PS beads (,0.39) and indicative of
substantial impediment to free diffusion. In contrast, the average
a-value for PS-PEG particles was ,0.70, reflecting motions
markedly less hindered by sputum across the time scales examined.
The diffusive nature and substantially faster speeds achieved with
muco-inert synthetic particles (d,200 nm; roughly 2.5 times
larger than AdV and nearly 10 times larger than AAV5), and the
markedly larger average pore size for CF sputum compared to the
size of both viral vectors, suggest that the hindered diffusion of
adenovirus and AAV5 cannot be attributed to steric hindrance
from a dense sputum mesh or to the high bulk viscoelasticity of CF
sputum. Instead, both viral vectors are likely trapped in sputum by
adhesion, and the small and hindered motions for AdV and AAV5
likely reflects, in part, thermal motions of mucin fibers to which the
viruses are bound.
Despite the slow ensemble averaged virus penetration speeds,
there may exist fast moving ‘outlier’ virions within the sample
capable of rapidly penetrating the sputum layer and, thus,
mediating gene transfer. To evaluate the effectiveness of the
sputum barrier, it is thus essential to measure the transport rates of
all individual viral particles and, in particular, the speeds of the
most rapidly moving fractions. The use of MPT allowed collection
of quantitative data on the transport of individual particles, data
that would otherwise be unavailable with ensemble methods such
as FRAP. We plotted the distribution of the logarithms of
individual particle effective diffusivities (Deff) at a time scale of 1 s
(Figure 3). Over 30% of the 200 nm PS-PEG particles exhibited
Deff values greater than 0.1 mm/sec
2, whereas only 0.4% and 0%
of AdV and PS particles, respectively, exhibited such speeds
(Figure 3). AAV5 had a higher fraction of faster moving particles,
with 9% of virions displaying speeds greater than 0.1 mm/sec
2.W e
used a Monte Carlo method that sorts the transport modes of
particles based on their time-scale independent effective diffusion
coefficients [12,15–17], and found that over 98% of AdV and 90%
of AAV were classified as either hindered or immobile, in good
agreement with the distribution of effective diffusivities (Figure 4).
It is not apparent whether the fast moving diffusive population of
AAV5 represents a phenotypically unique subset of virions due to
inherent vector packaging differences between individual virions,
as the ratio of genomic particles to infective particles of AAV
preparations can be as high as 200–10,000 [18]. It is unlikely that
the differences in viral mobility can be attributed to the
heterogeneity of the sputum microstructure, since the smallest
pores present in CF sputum (range: 60–300 nm [14]) are
substantially larger than the size of an AAV.
Based on our MSD measurements at short time scales, we used
Fick’s second law to estimate the fraction of AdV and AAV5 that
may penetrate a sputum layer of a given thickness over time
(Figure 5A). Although the thickness of CF sputum coating airways
epithelial cells varies from patient to patient, by location within the
respiratory tract, and likely depends on disease progression, most
estimates are in the range of 10–55 mm [19–21]. Assuming the
sputum layer to be 10 mm thick, only 0.4 and 2.7% of AdV and
AAV5 are expected to penetrate after one hour, respectively
(Figure 5B). In contrast, roughly 20% of the PS-PEG particles may
penetrate the sputum layer over the same duration. If the sputum
layer were 55 mm thick, we predict only 0.2% of AdV and 0.7% of
AAV5 would be capable of penetrating within one hour, as
compared to nearly 40% of PS-PEG particles.
While this analysis provides insight into the extent sputum may
serve as a barrier to viral vectors, the fraction of vectors that can
mediate gene transfer will likely be much smaller than this
estimate. Upon reaching the epithelial cells, the glycocalyx and the
paucity of receptors on the apical membrane further limit cell
entry [6,22]. The efficiency of AAV entry into unpolarized cells
was 13% [23] and likely even lower for polarized epithelium [24].
After endocytosis, numerous potentially rate-limiting intracellular
events must also be overcome for successful transduction [25,26].
Nevertheless, the limited gene carrier penetration observed here in
purulent CF sputum helps to explain the very poor gene transfer
observed with AAV in the human airways as compared to human
Figure 1. Sample 20 s trajectories. Representative trajectories of (A) Adenovirus (Adv), (B) AAV5, (C) muco-adhesive PS control nanoparticles and
(D) muco-inert control PS-PEG nanoparticles. All trajectories have MSD values within one standard deviation of the ensemble average.
doi:10.1371/journal.pone.0019919.g001
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tenacious barrier than sputum in human nares or mucus in the
lungs of other animals [27,28]. Previously, aerosol doses as high as
2.5610
10 infectious adenovirus (AdV) were administered to CF
patients, but #2.4% of airway cells were shown to contain nuclear
localized vector DNA, as estimated by fluorescence in situ
hybridization experiments [29]. A major Phase II clinical trial
utilizing AAV was also recently dropped due to inadequate
efficacy, even though efficient gene transfer was evident in both
rabbits and monkeys [30], as well as in the maxillary sinuses of
humans [31].
The extracellular fluids in the lung have long been considered
an integral part of a complex barrier that minimizes infections of
the airway epithelia. For example, the airway surface liquid has
both antimicrobial and antiviral properties, with high concentra-
tions of lysozyme [32] and antibodies [33]. Antibodies were found
to limit adenoviral infection of airway epithelium in both animal
models and humans [33–35]. In CF patients, proteins associated
with chronic inflammation, such as high concentrations of
uninhibited neutrophil elastase [36], may further decrease vector
efficiency. Recent studies have shown that bronchoalveolar lavage
[29] fluid from CF patients reduces both AdV and AAV2-
mediated gene transfer [37–39]. Although it has been reported
that AAV5 transduction is maintained in the presence of BAL
fluids from CF patients [40], 20% of the population harbor
neutralizing antibodies against AAV5 [41]. The results presented
here indicate that CF sputum can also act as a critical diffusional
barrier, trapping viral vectors via adhesion and, thereby, limiting
penetration. The reduced penetration speeds of viruses in sputum
are also likely to increase the probability of viral inactivation by
native protective mechanisms.
Although the specific nature of the adhesive interactions
between viral vectors and sputum constituents remain unclear, it
is likely a complex interplay of adhesion based on hydrophobic,
ionic, hydrogen-bonding and/or van der Waals interactions.
Mucins, the primary building block of CF sputum, are highly
flexible molecules that are densely glycosylated, and therefore
carry a negative charge due to the presence of carboxyl or sulfate
groups. In addition, they also contain periodic hydrophobic
‘‘naked’’ globular regions interspersed along the mucin fibers,
stabilized by multiple internal disulfide bonds [42]. Thus, mucins
may form hydrophobic, electrostatic and/or hydrogen bonding
adhesive interactions with foreign particles [43]. Elevated levels of
bacterial and endogenous DNA, as well as actin filaments from
degraded neutrophils in CF sputum, further contributes to its
dense mesh structure and increased adhesivity [43–45]. The high
density of adhesive domains, coupled with the highly flexible
nature of mucins and other macromolecules, allows formation of
multiple adhesive interactions with surfaces of foreign particles
[43]. Even if each adhesive interaction is low affinity and can be
readily disrupted by thermal energy, a large number of low-affinity
adhesive interactions with the sputum mesh can effectively
immobilize particles with permanent high viscidity [46]. Alterna-
tively, it is possible that some viruses may bind directly to specific
domains along mucins. For example, AAV4 binds to O-linked
sialic acids highly expressed on mucins in CF sputum, and
presence of MUC1 inhibited gene transfer with AAV4 [47]. While
AAV5 also binds to 2,3-linked sialic acids, AAV5 interacts with
sialic acids on N-linked carbohydrates which are rarely expressed
on mucins, and MUC1 did not block gene transfer with AAV5
[47].
Although a number of scientists initially speculated that only 6–
10% of airway epithelial cells need to have CFTR corrected to
restore Cl
2 transport in an in vitro cell culture model [48], it is
now thought that a larger number of cells must be transduced for
the normalization of both Cl
2 secretion and Na
+ absorption [49].
While the number of cells that need to be genetically corrected for
clinical benefit remains unresolved, improved gene carrier
penetration across the sputum layer is likely a critical step towards
more reliable gene transfer in the CF lung airways. Our results
suggest that engineering muco-inert surfaces on virus-sized
Figure 3. Distribution of logarithms of individual particle
effective diffusivities (Deff). Distributions of Deff of AdV, AAV5, PS
and PS-PEG particles represented as a percentage of particles in CF
sputum at a time scale of 1 s.
doi:10.1371/journal.pone.0019919.g003
Figure 4. Transport mode distributions of AdV, AAV5, PS and
PS-PEG particles. Particles were classified into either (i) immobile or
hindered and (ii) diffusive [12,15–17]. *Statistically significant difference
when compared with AAV5, AdV or PS within the same transport mode
classification (p,0.05).
doi:10.1371/journal.pone.0019919.g004
Figure 2. Averaged ensemble mean squared displacements
,MSD. of viral vectors and synthetic particles with respect to
time scale. Data represent n=5 independent experiments with ,100
particles tracked per experimental condition. Error bars represents
standard error. *Statistically significant difference when compared with
AAV5, AdV or PS (p,0.05).
doi:10.1371/journal.pone.0019919.g002
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CF sputum. One possible approach may be to engineer viral
vectors lacking specific surface epitopes that cause them to adhere
to sputum constituents. For example, Muzyczka and colleagues
have engineered AAV2 mutants without the normal heparin
sulfate binding of the virus and discovered that the mutant virus
produced a larger area of transduction upon injection in the striata
of rat brains (unpublished observations; personal communication).
This was presumably due to the increased diffusion of mutant
AAV2 in the brain. In the scenario where specific epitopes
responsible for mucoadhesion is not known, an alternative
approach may be to employ directed evolution techniques to
evolve non-mucoadhesive viruses. This approach is exemplified by
previous work that evolved AAV vectors more efficient at CFTR
delivery to human ciliated airway epithelium, or AAV vectors that
evade neutralizing antibodies [50,51].
Alternatively, vectorpenetration acrosssputummaybe enhanced
with adjuvant therapies targeted at reducing the barrier properties
of CF sputum, such as bronchoalveoloar lavage (BAL) to reduce
sputum, or clinically prescribed mucolytics that degrade specific
constituents of the sputum mesh [43]. Two commonly prescribed
mucolytic agents, N-acetyl-cysteine (NAC; Mucomyst H)a n d
recombinant human DNAse (rhDNAse; Pulmozyme H), have been
shown to reduce the bulk rheological properties of CF sputum [52–
54]. Dawson et al previously found that rhDNase treatment failed to
improve the diffusion of polystyrene nanoparticles in CF sputum
[7], whereas Suk et al showed that NAC markedly enhanced the
diffusion of coated, muco-inert nanoparticles in CF sputum, but not
the diffusion of uncoated particles that were muco-adhesive [55]. It
remains to be determined whether these mucolytic treatments will
enhance or hinder viral vector transport.
We have demonstrated that human CF sputum is likely a critical
barrier to overcome for successful CF gene therapy. Much of the
current effort on improving AAV vectors for CF gene therapy has
focused on identifying and characterizing novel variants of AAV
with improved lung tropism. For example, AAV serotype 1 and 6
has been shown to transduce airway epithelia in mice or polarized
human cell cultures significantly more efficiently than the most
widelytested serotype,AAV2 [56,57].Furthereffortshaveledtothe
development of AAV6.2, with a single point mutation and a 2-fold
improvement in the transduction of airway epithelium compared to
parental AAV6 vectors in both in vivo mouse studies and in vitro
human ciliated airway epithelium [58]. However, improved vector
penetration across sputum remains a critical step to reduce the viral
dosagenecessary forefficient transductioninthe CF lung.Ourwork
furthersuggeststhat hightransgeneexpression incellculture models
or in animal models may not be sufficient justification to initiate
clinical trials in CF patients without evidence that the same systems
are capable of penetrating sputum.
Materials and Methods
Ethics Statement
Sputum samples were collected at the Johns Hopkins Adult
Cystic Fibrosis Program conforming to ethical standards of the
Johns Hopkins Medicine Institutional Review Board. Written
informed consent was obtained from all participants.
Collection of Cystic Fibrosis Sputum
Same day samples were placed on ice upon collection, pooled
together to minimize patient-to-patient variability and used within
24 hrs. The barrier properties of collected sputum were confirmed
by tracking fluorescent polystyrene (PS) beads that undergo
polyvalent adhesive interactions with sputum [14].
Preparation of Fluorescent Viruses and Particles
Green fluorescent protein–labeled AdV was constructed and
generously provided by Dr. Curiel (University of Alabama).
AlexaFluor 488 labeled AAV5 was provided by Dr. Chiorini
(NIH). Fluorescent uncoated polystyrene nanoparticles with
carboxyl-modified surfaces (Molecular Probes, Eugene, OR) were
used as provided. PEG-coated nanoparticles were prepared by
covalently modified surface carboxyl groups with polyethylene
glycol (PEG) as described previously [12,14]. Size and f-potential
(surface charge) of nanoparticles were determined by Zetasizer
Nano ZS90 (Malvern Instruments, Southborough, MA) to confirm
dense PEG conjugation [12,59].
Multiple Particle Tracking (MPT)
Fluorescently labeled virions were added to ,30 mlo fC F
sputum at minimal dilution (3% v/v), placed in a custom made
glass chamber and incubated for 30 minutes prior to microscopy.
Figure 5. Theoretical model of particle penetration across a sputum layer. (A) Schematic of the model, where particles are deposited in
airway lumen on top of the CF sputum layer and must penetrate a 10 mm sputum layer to reach the epithelial cells. The pericilliary layer is much
smaller in CF patients due to the collapsed cilia from the accumulated sputum [60]. (B) Estimated fraction of viral and synthetic particles that are
capable of penetrating a 10 mm thick layer of CF sputum over time using Fick’s second law. *Statistically significant difference when compared with
AAV5, AdV or PS (p,0.05).
doi:10.1371/journal.pone.0019919.g005
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Photometrics, Tucson AZ) mounted on an inverted epifluores-
cence microscope (3-I Marianas, Zeiss, Thornwood, NY) equipped
with a 100X oil-immersion objective (numerical aperture 1.3).
Movies were recorded at a temporal resolution of 66.7 ms for 20 s
using Slidebook 4.2 Advanced Imaging software (Universal
Imaging Corp. Downington, PA). Movies were analyzed with
Metamorph software (Universal Imaging Corp. Downington, PA)
to extract x, y positional data over time. Time-averaged mean
square displacement (MSD) and effective diffusivity.
(Deff) for each particle were calculated as a function of time scale
(s) [12,14]. CF sputum was assumed to be locally isotropic but not
necessarily homogeneous; thus, 2D diffusivity is equal to 3D
diffusivity (see review [13] for more details). Five independent
experiments in sputum from different days, with n,100 virions
per experiment, were performed. Average transport rates were
calculated by geometric ensemble-averaging of individual trans-
port rates. Particle transport mechanism (immobile, hindered, and
diffusive) was classified as discussed previously [12,16]. Briefly, the
mechanism of particle transport over short and long time scales
was classified based on the concept of relative change (RC) of Deff.
RC values of particles at short and long time scales were calculated
by dividing the Deff of a particle at a probed time scale by the Deff
at an earlier reference time scale. By calculating RC values for two
time regimes (i.e., short and long time scales), one can obtain the
transport mode that describes the particle transport properties
over different length and temporal scales. Particles undergoing
hindered diffusion are expected to possess RC values below that
for typical diffusive particles. Due to the random nature of
diffusion, however, the RC values of a population of purely
diffusive particles will have a certain spread around the value 1.
Therefore, a Monte Carlo simulation of 10,000 random walks was
used to predict this distribution of RC values (please see [16] for
more details). The tracking resolution was 10 nm, as determined
by tracking particles immobilized with a strong adhesive [12,13].
Particle Penetration Model
Speeds of individual particles, obtained from particle tracking
data, were projected to 2 hours using the measured ,MSD.
versus t relationship. Concentration profiles over time were
obtained by numerically integrating Fick’s second law, du/dt =
Deff d
2u/dx
2 with the initial condition of particles present at the
apical side (u(x,0) =1 when x =0, u(x,0) =0 otherwise) and
boundary conditions of constant particle concentration at the
apical side (u(0,t) =1) and no flux out across the epithelium (du/
dx|x=10 =0).
Statistical Analysis
Statistical significance between two groups was determined with
the one-sided student’s t-test under the assumption of unequal
variance. P-values less than 0.05 were considered significant.
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